A novel respiratory syncytial virus strain led to infections in all but one of 20 healthy adults in a controlled human infection trial designed to evaluate the safety and infectious potential of ...

"How immunity to respiratory syncytial virus develops in childhood, deteriorates in adults." ScienceDaily. ScienceDaily, 21 April 2016. <www.sciencedaily.com / releases / 2016 / 04 / 160421145747 ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Since 1964, the US Centers for Disease Control and Prevention (CDC) had regularly reviewed the evidence on the safety and ...

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nature Communications, 2017; 8: 14158 DOI: 10.1038/NCOMMS14158 ...

ORAL PRESENTATION October 1, 2022, 09:45 – 10:00 BST “EDP-323, a Novel L-Protein Inhibitor for the Treatment of Respiratory Syncytial Virus,” Michael Rhodin, Ph.D., United States ...

Researchers reported the immunogenicity, efficacy, and safety of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic)-RSV (respiratory syncytial virus) vaccine against RSV-A (RSV subtype A ...

Electron microscope shows human respiratory syncytial virus (RSV) virions, colourised blue, and anti-RSV F protein/gold antibodies, colourised yellow, shedding from the surface of human lung cells ...

Respiratory Syncytial Virus (RSV) causes an infection of the lungs and respiratory tract. It is a very common virus and will infect most children by the time they turn two years old.